Oxidants and antioxidants in myocardial infarction (MI); Investigation of ischemia modified albumin, malondialdehyde, superoxide dismutase and catalase in individuals diagnosed with ST elevated myocardial infarction (STEMI) and non-STEMI (NSTEMI)
Oxidative Stress and Antioxidant status in ACS.
Abstract
Background: Coronary ischemia can lead to myocardial damage and necrosis. The pathogenesis of cardiovascular diseases often includes increased oxidative stress and decreased antioxidant defense. The study aimed to assess levels of ischemia modified albumin (IMA), malondialdehyde acid (MDA), superoxide dismutase (SOD), and catalase in individuals diagnosed with ST elevated myocardial infarction (STEMI) and non-STEMI.
Methods: The present study prospectively included 50 STEMI patients, 55 NSTEMI patients, and 55 healthy subjects. Only patients who were recently diagnosed with STEMI or NSTEMI were included in this study. IMA, MDA, SOD, and catalase activities were measured spectrophotometrically. Significant coronary artery lesions were determined by angiography.
Results: Patients with ACS had significantly greater IMA and MDA values than the healthy controls (p<0.001). In addition, patients with STEMI had IMA levels that were significantly greater than those of the patients with NSTEMI (p <0.001), while the reverse was true for MDA levels (p<0.001). The healthy controls had the highest levels of SOD and catalase levels, followed by patients with STEMI and patients with NSTEMI, respectively (p <0.001).
There was a significant negative correlation among MDA and SOD with catalase levels (r = -0.771 p <0.001 MDA vs catalase; r = -0.821 p <0.001 SOD vs catalase).
Conclusions: Data obtained in this study reveals that compared to healthy controls, STEMI and NSTEMI patients had increased levels MDA and IMA, and decreased levels of SOD and catalase.
References
2. Pantazopoulos I, Papadimitriou L, Dontas I, et al. Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 2009; 80: 306–310.
3. Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. The international journal of biochemistry & cell biology 2007; 39: 44–84.
4. Steinberg D, Witztum JL. Lipoproteins and atherogenesis: current concepts. Jama 1990; 264: 3047–3052.
5. Amaki T, Suzuki T, Nakamura F, et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. Heart 2004; 90: 1211–1213.
6. Matsuo Y, Kubo T, Okumoto Y, et al. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease. European Heart Journal–Cardiovascular Imaging 2013; 14: 43–50.
7. Kabaroglu C, Mutaf I il, Boydak B, et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta cardiologica 2004; 59: 606–611.
8. Nand N, Budhiraja N, Singh G, et al. Lipid peroxidation and vitamin E in ischemic heart disease. The Journal of the Association of Physicians of India 1997; 45: 839–842.
9. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365–372.
10. Dhalla NS, Elmoselhi AB, Hata T, et al. Status of myocardial antioxidants in ischemia–reperfusion injury. Cardiovascular research 2000; 47: 446–456.
11. Díaz-Araya G, Nettle D, Castro P, et al. Oxidative stress after reperfusion with primary coronary angioplasty: lack of effect of glucose-insulin-potassium infusion. Critical care medicine 2002; 30: 417–421.
12. Noichri Y, Chalghoum A, Chkioua L, et al. Low erythrocyte catalase enzyme activity is correlated with high serum total homocysteine levels in Tunisian patients with acute myocardial infarction. Diagnostic pathology 2013; 8: 68.
13. Serdar Z, Serdar A, Altin A, et al. The relation between oxidant and antioxidant parameters and severity of acute coronary syndromes. Acta cardiologica 2007; 62: 373–380.
14. Gammoudi I, Dandana A, Chahed H, et al. Evaluation of oxidative stress among coronary patients. IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE 2013; 28: 39–42.
15. Bar–Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia—a preliminary report. The Journal of emergency medicine 2000; 19: 311–315.
16. Young I, Trimble E. Measurement of malondialdehyde in plasma by high performance liquid chromatography with fluorimetric detection. Annals of clinical biochemistry 1991; 28: 504–508.
17. Elstner E, Youngman R, Obwald W. Superoxide dismutase. Methods of enzymatic analysis 1983; 3: 293–302.
18. Goth L. A simple method for determination of serum catalase activity and revision of reference range. Clinica chimica acta 1991; 196: 143–151.
19. Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug metabolism and pharmacokinetics 2009; 24: 333–341.
20. Erturk E, Cekic B, Geze S, et al. Comparison of the effect of propofol and N-acetyl cysteine in preventing ischaemia–reperfusion injury. European Journal of Anaesthesiology (EJA) 2009; 26: 279–284.
21. Sinha M, Roy D, Gaze D, et al. Role of “Ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Heart 2004; 90: 644–644.
22. Liyan C, Jie Z, Xiaozhou H. Prognostic value of combination of heart‐type fatty acid‐binding protein and ischemia‐modified albumin in patients with acute coronary syndromes and normal troponin T values. Journal of clinical laboratory analysis 2009; 23: 14–18.
23. Aggarwal K, Seth S, Dahiya K, et al. Ischemia modified albumin in patients of cardiac and non-cardiac chest pain.
24. Bali L, Cuisset T, Giorgi R, et al. Prognostic value of ischaemia-modified albumin in patients with non-ST-segment elevation acute coronary syndromes. Archives of cardiovascular diseases 2008; 101: 645–651.
25. Van Belle E, Dallongeville J, Vicaut E, et al. Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. American heart journal 2010; 159: 570–576.
26. Cikim G, Canatan H, Gursu MF, et al. Levels of zinc and lipid peroxidation in acute coronary syndrome. Biological trace element research 2003; 96: 61–69.
27. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999; 281: 1718–1721.
28. Amioka N, Miyoshi T, Otsuka H, et al. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Journal of cardiology 2019; 74: 258–266.
29. Gheddouchi S, Mokhtari-Soulimane N, Merzouk H, et al. Low SOD activity is associated with overproduction of peroxynitrite and nitric oxide in patients with acute coronary syndrome. Nitric Oxide 2015; 49: 40–46.
30. Himmetoglu S, Dincer Y, Bozcali E, et al. Oxidative DNA damage and antioxidant defense after reperfusion in acute myocardial infarction. Journal of Investigative Medicine 2009; 57: 595–599.
31. D’souza B, Vishwanath P, D’souza V. Oxidative injury and antioxidants in coronary artery bypass graft surgery: off-pump CABG significantly reduces oxidative stress. Clinica Chimica Acta 2007; 375: 147–152.
32. Bagatini MD, Martins CC, Battisti V, et al. Oxidative stress versus antioxidant defenses in patients with acute myocardial infarction. Heart and vessels 2011; 26: 55–63.
33. Kesavulu M, Rao BK, Giri R, et al. Lipid peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary heart disease. Diabetes research and clinical practice 2001; 53: 33–39.
34. Senthil S, Veerappan R, Rao MR, et al. Oxidative stress and antioxidants in patients with cardiogenic shock complicating acute myocardial infarction. Clinica Chimica Acta 2004; 348: 131–137.
35. Zhou X, Zhai X, Ashraf M. Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Circulation 1996; 93: 1177–1184.
36. Serdar Z, Aslan K, Dirican M, et al. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clinical biochemistry 2006; 39: 794–803.
Copyright (c) 2020 Nesim Aladağ, Ramazan Asoğlu, Mahmut Özdemir, Emin Asoğlu, Rukiye Derin Atabey, Canan Demir, Halit Demir
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.